← Madrigal Pharmaceuticals, Inc. (MDGL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Madrigal Pharmaceuticals, Inc. (MDGL)
Pharmaceutical Preparations · market cap $11.8B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
2
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Madrigal Pharmaceuticals (MDGL) is a ~$12.9B market-cap pharmaceutical company with 528 employees, built almost entirely around resmetirom, its lead asset approved/in Phase 3 for NASH (nonalcoholic steatohepatitis). The company generated $958M in 2025 revenue — a dramatic ramp from $180M in 2024 and zero in 2023 — indicating a commercial launch is underway, though it remains deeply unprofitable with a net loss of $288M in 2025. A critical near-term risk is an extremely thin cash runway of approximately 4.1 months (~$227M cash vs. $143M net debt), making near-term capital markets activity likely.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 3 · Resmetiromimp 9/10
- 2026-12-15 (est.)Phase 2 · Resmetiromimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Resmetirom | Phase 3 | NASH |
| MGL-3196 | Phase 3 | Heterozygous Familial Hypercholesterolemia |
Price & technical context
3-month
-5.4%
6-month
-5.7%
12-month
+11.3%
52-wk range
$412.35–$602.83
vs 50-day MA
-4.7%
vs 200-day MA
-2.2%
Realized vol
67.0%
Max drawdown
-30.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MDGL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.